Prostate cancer therapy for locally advanced and metastatic diseases includes androgen
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …

Metabolic reprogramming has been recognised as a hallmark in solid tumours. Malignant
modification of the tumour's bioenergetics provides energy for tumour growth and …

Continued exploration of the androgen receptor (AR) is crucial, as it plays pivotal roles in
diverse diseases such as prostate cancer (PCa), serving as a significant therapeutic focus …

Simple Summary Prostate cancer (PCa) is the second most common cancer in men and one
of the leading causes of death. Signal transducers and activators of transcription (STATs) …

Prostate-specific membrane antigen (PSMA) is an essential molecular regulator of prostate
cancer (PCa) progression coded by the FOLH1 gene. The PSMA protein has become an …

Androgen deprivation therapy (ADT) is the mainstay regimen in patients with androgen-
dependent prostate cancer (PCa). However, the selection of androgen-independent cancer …

Background/Aim: The cytoprotective heat shock protein 27 (HSP27) acts as a protein
chaperone, antioxidant, and apoptosis regulator and is involved in cytoskeletal remodeling …

Background/Aim: Androgen receptor (AR) degradation is the primary regulator of androgen
receptor activity. This study was designed to investigate the influence of the proteasome on …

To alleviate metastatic castration-resistant prostate cancer (mCRPC), enzalutamide, a non-
steroidal antiandrogen, is employed. Following androgen deprivation therapy or anti …

Antiandrogen therapy is a primary treatment for patients with metastasized prostate cancer.
Whilst the biologic mechanisms of antiandrogens have been extensively studied, the …